Sana Biotechnology, Inc. (SANA)
After hours:
- GlobeNewswire
Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference
SEATTLE, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Guggenheim Healthcare Talks 5th Annual Oncology Conference at 1:00 p.m. ET on Thursday, February 9, 2023. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Rela
- GlobeNewswire
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
Goal is to report initial SC291 clinical data this year Goal is to submit a second IND from the platform this year for SC262, a hypoimmune-modified CD22-targeted allogeneic CAR T therapy SEATTLE, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to initiate a first-in-h
- GlobeNewswire
Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 41st Annual J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Tuesday, January 10, 2023. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of
